Resistance Patterns in Second-Line Sensitization Tests and Their Effect on MDR-TB Treatment Success in Relapsed and Failed Cases
DOI:
https://doi.org/10.33533/jpm.v18i2.9445Keywords:
Relapse, rekurrence, Failure, Treatment, Tuberculosis, Disease outcome, SensitivityAbstract
Tuberculosis recurrence is caused by reinfection with Mycobacterium tuberculosis that has already been experienced or infection with a new strain of bacteria. The increasing incidence of TBMDR in the community accelerates the spread of TBMDR. Objective: To identify TBMDR treatment failure in relapse cases, and category 1 and 2 treatment failure. Method: Retrospective. Secondary data from the Ministry of Health SITB, 2017-2019 period shows that the sample size of relapses, category 1 and 2 treatment is 466 patients. Results: the relapse bivariate test and treatment failure categories 1 and 2 obtained a p-value of <0.05 (age 17-about 60 years and second-line sensitivity test). They are affected by HIV status. The regression results of the second sensitization test strongly influenced TB-relapsed patients to fail, dropout, and complete treatment compared to cured treatment patients, still-relapsed 17-44 years old patients, and category 1 and 2 treatment failure were more likely to be LFU than recover, and the second sensitivity test affected treatment failure and completion rather than recovery, although HIV status did not affect treatment outcomes. Conclusion: Strategy to reduce the rate of recurrence and conversion failure by examining genetic mutations (biomarkers) of M. tuberculosis.
Keywords: Relapse, treatment failure, sensitization test, outcome treatment.
References
Lestari BW, Nijman G, Larasmanah A, Soeroto AY, Santoso P, Alisjahbana B, et al. Management of drug-resistant tuberculosis in Indonesia: a four-year cascade of care analysis. The Lancet Regional Health - Southeast Asia. 2024 Mar 1;22.DOI: https://doi.org/10.1016/j.lansea.2023.100294
World Health Organization. Global Tuberculosis Report 2023. World Health Organization; 2023.
Direktorat Jenderal Pencegahan dan Pengendalian Penyakit (P2P) Kementerian Kesehatan Republik Indonesia. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resisten Obat di Indonesia. Jakarta: Kementerian Kesehatan RI; 2020.
Saputri IN, Munthe EL. Tuberkulosis resisten ganda (tb-mdr) dan implementasi upaya pengendalian di kabupaten ketapang. Jurnal Respirologi Indonesia. 2020 Jan;40(1):6–15.DOI: https://doi.org/10.36497/jri.v40i1.91
NIAID. Tuberculosis drugs and mechanisms of action. NIAID : National Institute of Allergy and Infectious Disease. 2024;1–8.
Tanuwiharja BY. Masalah TB paru resisten. Perhimpunan Dokter Paru Indonesia. 2004;
Umar FF, Husain DR, Hatta MM, Natzir RR, Sjahril RS, Dwiyanti RR, et al. Molecular characterisation of mutations associated with resistance to first- and second-line drugs among Indonesian patients with tuberculosis. J Taibah Univ Med Sci. 2020 Feb 1;15(1):54–8.DOI: https://doi.org/10.1016/j.jtumed.2019.12.003
McIvor A, Koornhof H, Kana BD. Relapse, re-infection, and mixed infections in tuberculosis disease. Pathog Dis. 2017 Apr 1;75(3). DOI: https://doi.org/10.1093/femspd/ftx020
Zong Z, Huo F, Shi J, Jing W, Ma Y, Liang Q, et al. Relapse versus reinfection of recurrent tuberculosis patients in a national tuberculosis specialized hospital in Beijing, China. Front Microbiol. 2018 Aug 14;9.DOI: https://doi.org/10.3389/fmicb.2018.01858
Maghradze N, Jugheli L, Borrell S, Tukvadze N, Aspindzelashvili R, Avaliani Z, et al. Classifying recurrent Mycobacterium tuberculosis cases in Georgia using MIRU-VNTR typing. PLoS One. 2019 Oct 1;14(10). https://doi.org/10.1371/journal.pone.0223610
Cucunawangsih, Wiwing V, Widysanto A, Lugito NPH. Mycobacterium tuberculosis resistance pattern against first-line drugs in patients from urban areas. Int J Mycobacterial. 2015 Dec 1;4(4):302–5. https://doi.org/10.1016/j.ijmyco.2015.08.002
Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: Where do they come from? BMC Infect Dis. 2017 Jan 6;17(1).DOI: https://doi.org/10.1186/s12879-016-2171-1
Sumardi. Mengenal tuberkulosis resisten obat (Multidrug Resistant Tuberculosis). Tim Kerja Hukum dan Hubungan Masyarakat RSUP Dr Sardjito Yogyakarta. 2019.
Wollenberg K, Harris M, Gabrielian A, Ciobanu N, Chesov D, Long A, et al. A retrospective genomic analysis of drug-resistant strains of M. tuberculosis in a high-burden setting, with an emphasis on comparative diagnostics and reactivation and reinfection status. BMC Infect Dis. 2020 Jan 7;20(1). DOI: https://doi.org/10.1186/s12879-019-4739-z
Cegielski JP, Kurbatova E, Van Der Walt M, Brand J, Ershova J, Tupasi T, et al. Multidrug- resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clinical Infectious Diseases. 2015 Nov 4;62(4):418–30.
Butov D, Myasoedov V, Gumeniuk M, Gumeniuk G, Choporova O, Tkachenko A, et al. Treatment effectiveness and outcome in patients with a relapse and newly diagnosed multidrug-resistant pulmonary tuberculosis. Med Glas. 2020 Aug 1;17(2):356–62.DOI: https://doi.org/10.17392/1179-20
McBryde ES, Meehan MT, Doan TN, Ragonnet R, Marais BJ, Guernier V, et al. The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains. International Journal of Infectious Diseases. 2017 Mar 1;56:14–20. DOI: https://doi.org/10.1016/j.ijid.2017.01.031
Adiwinata R, Rasidi J, Marpaung M. Clinical profile and treatment evaluation of rifampicin- resistant and multidrug-resistant tuberculosis patients at Dr. Kanujoso Djatiwibowo Public Hospital, Balikpapan. J Respir Indo. 2018;38(3). DOI: https://doi.org/10.36497/jri.v38i3.2
Afshar B, Carless J, Roche A, Balasegaram S, Anderson C. Surveillance of tuberculosis (TB) cases attributable to relapse or reinfection in London, 2002-2015. PLoS One. 2019 Feb 1;14(2). DOI: https://doi.org/10.1371/journal.pone.0211972
Alene KA, Yi H, Viney K, McBryde ES, Yang K, Bai L, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis. 2017 Aug 16;17(1). DOI: https://doi.org/10.1186/s12879-017-2662-8
Jaber AAS, Ibrahim B. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: Data from centres with high drug resistance. BMC Infect Dis. 2019 May 24;19(1).DOI: https://doi.org/10.1186/s12879-019-4069-1
Rockwood N, Bruyn E, Morris T, Wilkinson RJ. Assessment of treatment response in tuberculosis. Expert Rev Respir Med. 2016 Jun 2;10(6):643–54. DOI: https://doi.org/10.1586/17476348.2016.1166960
Azarian T. The importance of pathogen whole-genome sequencing in evaluating interventions to reduce the spread of multidrug-resistant organisms in the healthcare setting. Clinical Infectious Diseases. 2021 Jun 1;72(11):1888–90. DOI: https://doi.org/10.1093/cid/ciaa724
Xu C, Li R, Shewade HD, Jeyashree K, Ruan Y, Zhang C, et al. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors. PLoS One. 2019 Apr 1;14(4). DOI: https://doi.org/10.1371/journal.pone.0214943
Yu MC, Chiang CY, Lee JJ, Chien ST, Lin CJ, Lee SW, et al. Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: Tackling loss to follow-up. Clinical Infectious Diseases. 2018 Jul 2;67(2):202–10. DOI: https://doi.org/10.1093/cid/ciy066
Khan I, Ahmad N, Khan S, Muhammad S, Khan AS, Ahmad I, et al. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. J Infect Public Health. 2019 Nov 1;12(6):809–15. DOI: https://doi.org/10.1016/j.jiph.2019.04.009
Saifullah A, Mallhi TH, Khan YH, Iqbal MS, Alotaibi NH, Alzarea AI, et al. Evaluation of risk factors associated with the development of MDR-and XDR-TB in a tertiary care hospital: A retrospective cohort study. PeerJ. 2021 Mar 18;9. DOI: https://doi.org/10.7717/peerj.10826
Hamdouni M El, Bourkadi JE, Benamor J, Hassar M, Cherrah Y, Ahid S. Treatment outcomes of drug resistant tuberculosis patients in Morocco: Multi-centric prospective study. BMC Infect Dis. 2019 Apr 11;19(1). DOI: https://doi.org/10.1186/s12879-019-3931-5
Abedipour F, Tirabadi NM, Khodaverdi E, Roham M. A review of drug-resistant tuberculosis, risk factors and tb epidemiology and incidence in Sistan and Baluchestan Province. Europian Journal of Molecular & Clinical Medicine. 2020;7(11):4435–43.
Sadykova L, Abramavičius S, Maimakov T, Berikova E, Kurakbayev K, Carr NT, et al. A retrospective analysis of treatment outcomes of drug-susceptible TB in Kazakhstan, 2013- 2016. Medicine. 2019 Jun 1;98(26). DOI: https://doi.org/10.1097/MD.0000000000016071
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright Notice
All articles submitted by the author and published in the Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan, are fully copyrighted by the publication of Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan under the Creative Commons Attribution-NonCommercial 4.0 International License by technically filling out the copyright transfer agreement and sending it to the publisher
Note :
The author can include in separate contractual arrangements for the non-exclusive distribution of rich versions of journal publications (for example: posting them to an institutional repository or publishing them in a book), with the acknowledgment of their initial publication in this journal.
Authors are permitted and encouraged to post their work online (for example: in an institutional repository or on their website) before and during the submission process because it can lead to productive exchanges, as well as earlier and more powerful citations of published works. (See Open Access Effects).
